GLP-1 Results at 6 Months: Halfway Progress Review

Quick Answer

At 6 months on GLP-1, the average weight loss is approximately 10–12% of starting body weight on semaglutide and 13–16% on tirzepatide. For someone starting at 220 lbs, that's 22–26 lbs on semaglutide and 29–35 lbs on tirzepatide. The 6-month mark is typically when weight loss is at its fastest weekly rate — nearing the maintenance dose.

Six Months: The Peak Efficacy Window

Counterintuitively, the period between months 4–7 often contains the fastest weekly weight loss — not months 1–3. By month 6:

Semaglutide patients are at or near the 2.4 mg maintenance dose
Tirzepatide patients are typically at 10–15 mg
The full appetite-suppressing effect is established
Side effects have usually resolved substantially
Dietary habits have adapted to lower portions

This combination of maximum dose, adapted physiology, and reduced side effects makes month 4–7 the most productive phase for most patients.

Average Results at 6 Months

From clinical trial week-by-week data (approximately week 24–28):

Semaglutide 2.4 mg:

Average weight loss at week 24: approximately -10.5% of body weight
In pounds: ~19–21 lbs for a 200 lb person

Tirzepatide 15 mg:

Average weight loss at week 24: approximately -15% of body weight
In pounds: ~27–30 lbs for a 200 lb person

Six-Month Results by Starting Weight

Starting Weight	Sema ~10.5%	Tirz ~15%
200 lbs	21 lbs → 179 lbs	30 lbs → 170 lbs
220 lbs	23 lbs → 197 lbs	33 lbs → 187 lbs
250 lbs	26 lbs → 224 lbs	37 lbs → 213 lbs
280 lbs	29 lbs → 251 lbs	42 lbs → 238 lbs
300 lbs	31 lbs → 269 lbs	45 lbs → 255 lbs

Health Changes Beyond Weight at 6 Months

Six months of GLP-1 therapy produces changes that go well beyond the scale:

Blood pressure: Average reduction of 3–6 mmHg systolic in hypertensive patients. Many patients can reduce antihypertensive medication doses under medical supervision.

Glycemic control: HbA1c typically drops 0.5–1.5% in prediabetic and diabetic patients. Fasting glucose often normalizes in prediabetes.

Cholesterol: Triglycerides typically fall 15–20%. LDL changes are more modest but directionally positive.

Sleep apnea: A 2024 trial (SURMOUNT-OSA) showed tirzepatide reduced apnea-hypopnea index by 24–25% at 52 weeks — significant enough that some patients no longer need CPAP.

Joint pain: Reduction in mechanical load from weight loss produces meaningful improvement in knee and hip pain by month 6 for most patients.

Quality of life: Multiple validated quality-of-life measures show significant improvement at 6 months in GLP-1 trials.

The Plateau That Begins to Emerge

While month 6 still often shows strong results, the first signs of plateau can appear. The body's adaptive mechanisms — reduced metabolic rate, increased metabolic efficiency — begin to counteract the caloric deficit created by appetite suppression.

This is normal and expected. It does not mean the medication stopped working. Options if plateau appears at month 6:

Ensure you're at maximum tolerated dose
Add resistance training to preserve metabolic rate
Slightly increase protein intake
Review dietary patterns for "caloric creep"

The plateau typically becomes more pronounced after month 9–12.

Start GLP-1 Treatment — Results Build Over 6+ Months

Bottom Line

Six months on GLP-1 represents approximately two-thirds of total expected weight loss and often contains the most productive weeks of the treatment course. Most patients describe month 6 as the point where results become clearly visible to others and health metrics show objective improvement.